Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience

Individualized patient care during PARPi maintenance therapy

Date

21 Sep 2021

Session

GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience

Presenters

Antonio González-Martín

Authors

A. González-Martín

Author affiliations

  • Medical Oncology, Grupo Español de Investigación en Cáncer de Ovario (GEICO), Clínica Universidad de Navarra, Madrid/ES
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings